Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 2, 1998, Pages 282-288

  Odds, F C ^a   Van Gerven, F ^a   Espinel Ingroff, A ^b   Bartlett, M S ^c   Ghannoum, M A ^d   Lancaster, M V ^e   Pfaller, M A ^f   Rex, J H ^g   Rinaldi, M G ^h   Walsh, T J ⁱ  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^d Department of Dermatology   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f UNIVERSITY OF IOWA   (United States)

^g UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^h Mays Cancer Center at UT Health San Antonio   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; CHLORMETHINE; CYCLOPHOSPHAMIDE; ITRACONAZOLE;

ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; ASCOMYCETES; ASPERGILLUS; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG EFFICACY; EXPERIMENTAL INFECTION; FUSARIUM; GUINEA PIG; IN VITRO STUDY; IN VIVO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; RHIZOPUS;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; DISEASE MODELS, ANIMAL; FUSARIUM; GUINEA PIGS; ITRACONAZOLE; MADUROMYCOSIS; MICE; MICROBIAL SENSITIVITY TESTS; PSEUDALLESCHERIA; STATISTICS; TREATMENT OUTCOME;

EID: 0031893541     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Albert, M. M., J. R. Graybill, and M. G. Rinaldi. 1991. Treatment of murine cryptococcal meningitis with an SCH-39304-amphotericin B combination. Antimicrob. Agents Chemother. 35:1721-1725.
2. Anaissie, E. J., N. C. Karyotakis, R. Hachem, M. C. Dignani, J. H. Rex, and V. Paetznick. 1994. Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J. Infect. Dis. 170:384-389.
3. Ashman, R. B., E. M. Bolitho, and A. Fulurija. 1995. Cytokine mRNA in brain tissue from mice that show strain-dependent differences in the severity of lesions induced by systemic infection with Candida albicans yeast. J. Infect. Dis. 172:823-830.
4. Barchiesi, F., L. K. Najvar, M. F. Luther, G. Scalise, M. G. Rinaldi, and J. R. Graybill. 1996. Variation in fluconazole efficacy for Candida albicans strains sequential isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model. Antimicrob. Agents Chemother. 40:1317-1320.
5. Clemons, K. V., and D. A. Stevens. 1992. Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis. J. Antimicrob. Chemother. 30:353-363.
6. Colombo, A. L., D. A. McGough, and M. G. Rinaldi. 1994. Discrepancies between MIC and MLC values of amphotericin B against isolates of Aspergillus species. Mycopathologia 128:129-133.
7. Costantino, P. J., N. F. Gare, and J. R. Warmington. 1995. Humoral immune responses to systemic Candida albicans infection in inbred mouse strains. Immunol. Cell. Biol. 73:125-133.
8. Denning, D. W., J. Y. Lee, J. S. Hostetler, P. Pappas, C. A. Kauffman, D. H. Dewsnup, J. N. Galgiani, J. R. Graybill, A. M. Suger, A. Catanzaro, H. Galli, J. R. Perfect, B. Dockery, W. E. Dismukes, and D. A. Stevens. 1994. NIAID mycoses study group multicenter trial of oral itraconazole therapy of invasive aspergillosis. Am. J. Med. 97:135-144.
9. Espinel-Ingroff, A., and T. M. Kerkering. 1991. Spectrophotometric method of inoculum preparation for the in vitro susceptibility testing of filamentous fungi. J. Clin. Microbiol. 29:393-394.
10. Espinel-Ingroff, A., J. H. Rex, R. Bowden, P. Menezes, M. Bartlett, M. McGinnis, C. Cooper, F. C. Odds, M. Pfaller, S. A. Messer, P. W. Nelson, M. G. Rinaldi, A. Fothergill, G. Shankland, T. J. Walsh, J. Peter, I. Weitzman, and N. X. Chin. 1996. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J. Clin. Microbiol. 35:139-143.
11. Espinel-Ingroff, A., K. Dawson, M. Pfaller, E. Anaissie, B. Breslin, D. Dixon, A. Fothergill, J. Peter, M. Rinaldi, and T. Walsh. 1995. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob. Agents Chemother. 39:314-319.
12. Graybill, J. R., and R. Bocanegra. 1995. Liposomal amphotericin B therapy of murine histoplasmosis. Antimicrob. Agents Chemother. 39:1885-1887.
13. Legrand, C., E. Anaissie, R. Hashem, P. Nelson, G. P. Bodey, and J. Ro. 1991. Experimental fusarial hyalohyphomycosis in a murine model. J. Infect. Dis. 164:944-948.
14. Matsumoto, T., L. Ajello, T. Matsuda, P. J. Szaniszlo, and T. J. Walsh. 1994. Developments in hyalohyphomycosis and phaeohyphomycosis. J. Med. Vet. Mycol. 32(Suppl. 1):329-349.
15. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Villanova, Pa.
16. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
17. Van Cutsem, J. 1990. Oral and parenteral treatment with itraconazole in various superficial and systemic experimental fungal infections. Comparisons with other antifungals and combination therapy. Br. J. Clin. Pract. Suppl. 71:32-40.
18. Vartivarian, S. E., E. J. Anaissie, and G. P. Bodey. 1993. Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin. Infect. Dis. 17(Suppl. 2):S487-S491.
19. Velez, J. D., R. Allendoerfer, M. Luther, M. G. Rinaldi, and J. R. Graybill. 1993. Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J. Infect. Dis. 168:508-510.
20. Walsh, T. J., K. Garrett, E. Feuerstein, M. Girton, M. Allende, J. Bacher, A. Francesconi, R. Schaufele, and P. A. Pizzo. 1995. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy. Antimicrob. Agents Chemother. 39:1065-1069.
21. Walsh, T. J., J. W. Lee, G. P. Melcher, E. Navarro, J. Bacher, D. Callender, K. D. Reed, T. Wu, G. Lopez-Berestein, and P. A. Pizzo. 1992. Experimental Trichosporon infection in persistently granulocytopenic rabbits - implications for pathogenesis, diagnosis and treatment of an emerging opportunistic mycosis. J. Infect. Dis. 166:121-133.
22. Walsh, T. J., J. W. Lee, E. Roilides, P. Francis, J. Bacher, C. A. Lyman, and P. A. Pizzo. 1992. Experimental antifungal chemotherapy in granulocytopenic animal models of disseminated candidiasis - approaches to understanding investigational antifungal compounds for patients with neoplastic diseases. Clin. Infect. Dis. 14:S139-S147.
23. Walsh, T. J., G. Melcher, M. Rinaldi, J. Lecciones, D. McGough, J. Lee, D. Callender, M. Rubin, and P. A. Pizzo. 1990. Trichosporon beigelii: an emerging pathogen resistant to amphotericin B. J. Clin. Microbiol. 28:1616-1622.
24. Walsh, T. J., J. Peter, D. A. McGough, A. W. Fothergill, M. G. Rinaldi, and P. A. Pizzo. 1995. Activity of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob. Agents Chemother. 39:1361-1364.
25. Woestenborghs, R., W. Lorreyne, and J. Heykants. 1987. Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography. J. Chromatogr. Biomed. Appl. 413:332-337.